Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects

Background. Daikenchuto (DKT) is a Kampo medicine used for the treatment of constipation. In this study, we evaluated the effectiveness of DKT against constipation. Patients and Methods. Thirty-three patients administered DKT for constipation were selected and divided into low-dose (7.5 g DKT; n=22)...

Full description

Bibliographic Details
Main Authors: Tatsuya Hirose, Yasutaka Shinoda, Ayaka Kuroda, Aya Yoshida, Machiko Mitsuoka, Kouki Mori, Yuki Kawachi, Akihiro Moriya, Kouji Tanaka, Atsuko Takeda, Tomoaki Yoshimura, Tadashi Sugiyama
Format: Article
Language:English
Published: Hindawi Limited 2018-01-01
Series:International Journal of Chronic Diseases
Online Access:http://dx.doi.org/10.1155/2018/1296717
id doaj-59eeec9b70d54774b3eb74046cba3b0a
record_format Article
spelling doaj-59eeec9b70d54774b3eb74046cba3b0a2020-11-24T23:44:26ZengHindawi LimitedInternational Journal of Chronic Diseases2356-69812314-57492018-01-01201810.1155/2018/12967171296717Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical EffectsTatsuya Hirose0Yasutaka Shinoda1Ayaka Kuroda2Aya Yoshida3Machiko Mitsuoka4Kouki Mori5Yuki Kawachi6Akihiro Moriya7Kouji Tanaka8Atsuko Takeda9Tomoaki Yoshimura10Tadashi Sugiyama11Department of Pharmacy, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki-shi, Gifu 503-8502, JapanDepartment of Pharmacy, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki-shi, Gifu 503-8502, JapanDepartment of Pharmacy, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki-shi, Gifu 503-8502, JapanDepartment of Pharmacy, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki-shi, Gifu 503-8502, JapanDepartment of Pharmacy, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki-shi, Gifu 503-8502, JapanDepartment of Pharmacy, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki-shi, Gifu 503-8502, JapanDepartment of Pharmacy, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki-shi, Gifu 503-8502, JapanDepartment of Pharmacy, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki-shi, Gifu 503-8502, JapanDepartment of Pharmacy, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki-shi, Gifu 503-8502, JapanDepartment of Pharmacy, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki-shi, Gifu 503-8502, JapanDepartment of Pharmacy, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki-shi, Gifu 503-8502, JapanLaboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, 1-25-4 Daigagu-nishi, Gifu-shi 501-1196, JapanBackground. Daikenchuto (DKT) is a Kampo medicine used for the treatment of constipation. In this study, we evaluated the effectiveness of DKT against constipation. Patients and Methods. Thirty-three patients administered DKT for constipation were selected and divided into low-dose (7.5 g DKT; n=22) and high-dose (15 g DKT; n=11) groups. We retrospectively evaluated weekly defaecation frequency, side effects, and clinical laboratory data. Results. Median defaecation frequencies after DKT administration (5, 5.5, 5, and 8 for the first, second, third, and fourth weeks, resp.) were significantly higher than that before DKT administration (2) in all 33 cases (P<0.01). One case (3%) of watery stool, one case of loose stools (3%), and no cases of abdominal pain (0%) were observed. Median defaecation frequencies in the high-dose group (7 and 9) were significantly higher than those in the low-dose group (4 and 3) in the first (P=0.0133) and second (P=0.0101) weeks, respectively. There was no significant change in clinical laboratory values. Conclusion. We suggest that DKT increases defaecation frequency and is safe for treating constipation.http://dx.doi.org/10.1155/2018/1296717
collection DOAJ
language English
format Article
sources DOAJ
author Tatsuya Hirose
Yasutaka Shinoda
Ayaka Kuroda
Aya Yoshida
Machiko Mitsuoka
Kouki Mori
Yuki Kawachi
Akihiro Moriya
Kouji Tanaka
Atsuko Takeda
Tomoaki Yoshimura
Tadashi Sugiyama
spellingShingle Tatsuya Hirose
Yasutaka Shinoda
Ayaka Kuroda
Aya Yoshida
Machiko Mitsuoka
Kouki Mori
Yuki Kawachi
Akihiro Moriya
Kouji Tanaka
Atsuko Takeda
Tomoaki Yoshimura
Tadashi Sugiyama
Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects
International Journal of Chronic Diseases
author_facet Tatsuya Hirose
Yasutaka Shinoda
Ayaka Kuroda
Aya Yoshida
Machiko Mitsuoka
Kouki Mori
Yuki Kawachi
Akihiro Moriya
Kouji Tanaka
Atsuko Takeda
Tomoaki Yoshimura
Tadashi Sugiyama
author_sort Tatsuya Hirose
title Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects
title_short Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects
title_full Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects
title_fullStr Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects
title_full_unstemmed Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects
title_sort efficacy and safety of daikenchuto for constipation and dose-dependent differences in clinical effects
publisher Hindawi Limited
series International Journal of Chronic Diseases
issn 2356-6981
2314-5749
publishDate 2018-01-01
description Background. Daikenchuto (DKT) is a Kampo medicine used for the treatment of constipation. In this study, we evaluated the effectiveness of DKT against constipation. Patients and Methods. Thirty-three patients administered DKT for constipation were selected and divided into low-dose (7.5 g DKT; n=22) and high-dose (15 g DKT; n=11) groups. We retrospectively evaluated weekly defaecation frequency, side effects, and clinical laboratory data. Results. Median defaecation frequencies after DKT administration (5, 5.5, 5, and 8 for the first, second, third, and fourth weeks, resp.) were significantly higher than that before DKT administration (2) in all 33 cases (P<0.01). One case (3%) of watery stool, one case of loose stools (3%), and no cases of abdominal pain (0%) were observed. Median defaecation frequencies in the high-dose group (7 and 9) were significantly higher than those in the low-dose group (4 and 3) in the first (P=0.0133) and second (P=0.0101) weeks, respectively. There was no significant change in clinical laboratory values. Conclusion. We suggest that DKT increases defaecation frequency and is safe for treating constipation.
url http://dx.doi.org/10.1155/2018/1296717
work_keys_str_mv AT tatsuyahirose efficacyandsafetyofdaikenchutoforconstipationanddosedependentdifferencesinclinicaleffects
AT yasutakashinoda efficacyandsafetyofdaikenchutoforconstipationanddosedependentdifferencesinclinicaleffects
AT ayakakuroda efficacyandsafetyofdaikenchutoforconstipationanddosedependentdifferencesinclinicaleffects
AT ayayoshida efficacyandsafetyofdaikenchutoforconstipationanddosedependentdifferencesinclinicaleffects
AT machikomitsuoka efficacyandsafetyofdaikenchutoforconstipationanddosedependentdifferencesinclinicaleffects
AT koukimori efficacyandsafetyofdaikenchutoforconstipationanddosedependentdifferencesinclinicaleffects
AT yukikawachi efficacyandsafetyofdaikenchutoforconstipationanddosedependentdifferencesinclinicaleffects
AT akihiromoriya efficacyandsafetyofdaikenchutoforconstipationanddosedependentdifferencesinclinicaleffects
AT koujitanaka efficacyandsafetyofdaikenchutoforconstipationanddosedependentdifferencesinclinicaleffects
AT atsukotakeda efficacyandsafetyofdaikenchutoforconstipationanddosedependentdifferencesinclinicaleffects
AT tomoakiyoshimura efficacyandsafetyofdaikenchutoforconstipationanddosedependentdifferencesinclinicaleffects
AT tadashisugiyama efficacyandsafetyofdaikenchutoforconstipationanddosedependentdifferencesinclinicaleffects
_version_ 1725498558676729856